Coronary Artery Disease
The OPERA study: The tenor or baritone of shorter duration of DAPT?
Josephine L. Warren,
Josephine L. Warren
Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, New York
Search for more papers by this author Roxana Mehran MD,
Corresponding Author
Roxana Mehran MD
Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, New York
Correspondence to: Roxana Mehran; Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574. E-mail:
[email protected]Search for more papers by this author
Josephine L. Warren,
Josephine L. Warren
Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, New York
Search for more papers by this author Roxana Mehran MD,
Corresponding Author
Roxana Mehran MD
Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, New York
Correspondence to: Roxana Mehran; Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574. E-mail:
[email protected]Search for more papers by this author
First published: 20 August 2014
No abstract is available for this article.
REFERENCES
- 1
Levine GN,
Bates ER,
Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: A report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation 2011; 124: 2574–2609.
- 2 European Association for Percutaneous Cardiovascular Interventions,
Wijns W,
Kolh P,
Danchin N, et al. Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS). Eur Heart J 2010; 31: 2501–2555.
- 3National Institute for Health and Clinical Excellence. Clinical guideline 48: MI: secondary prevention in primary and secondary care for patients following a myocardial infarction. London: NICE, 2013. www.nice.org.uk/CG4172
- 4
Cassese S,
Byrne RA,
Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 2012; 33: 3078–3087.
- 5
Feres F,
Costa RA,
Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The optimize randomized trial. JAMA 2013; 310: 2510–2522.
